Increasing Innovation in R&D - Seizing early stage external growth opportunities

Transcription

1 Increasing Innovation in R&D - Seizing early stage external growth opportunities Paul R. Eynott, PhD sanofi-aventis, US [email protected] -1- Sommaire

2 -2- CHRISTOPHER A. VIEHBACHER Chief Executive Officer Sanofi-aventis ambition is to become a diversified global healthcare leader, focused on patients needs. 2

3 Group Profile -3- A global healthcare leader # 1 in emerging markets (1) with a broad and balanced presence Approximately 105,000 employees in 110 countries A diversified offering of medicines, consumer heath care products and generics A world leader in human vaccines A global leader in animal health 2009 net sales: 29.3 billion in increase of 6.3% (2) 33 partnerships and acquisitions (1) World excluding the United States, Canada, Western Europe (France, Germany, United Kingdom, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Sweden, Portugal, the Netherlands, Austria, Switzerland, Ireland, Finland, Norway, Iceland, Denmark), Japan, Australia and New Zealand. (2) Compared to 2008 on a reported basis March 2010

4 -4- Group strategy is based on three key principles to deliver long-term sustainable growth : 1 INCREASING INNOVATION IN R&D 2 SEIZING EXTERNAL GROWTH OPPORTUNITIES 3 ADAPTING GROUP STRUCTURES FOR FUTURE CHALLENGES

5 R&D Focus Cliquez pour modifier le style du titre Our strategic vision for R&D focuses on six major areas with critical unmet medical needs : ONCOLOGY FIBROSIS & WOUND REPAIR INFECTIOUS DISEASES DIABETES -5- IMMUNO- INFLAMMATION AGING AGING 5

6 From Partners to Network Cliquez pour modifier le style du titre -6- Our objective is to find new solutions to address individual patient s needs. MARC CLUZEL Executive Vice président Research&Development To deliver our objectives, we focus on : Networks Partnerships & Collaborations Across regions Technologies and areas of excellence 6

7 Diabetes Fibrosis Infectious diseases Ophtalmology Oncology Key Areas -7- Immunoinflammation Aging Microfluidics/ Nanofluidics Regenerative Medicine / Stem cells Personalized Medicine Emerging Platforms Technologies Modeling of biological systems Drug delivery solutions E-health Biologicals Nanotechnologies 7

8 -8- Take on validated concepts and early stage leads, coming from sanofi-aventis or from academic or biotech partners, and transform them into pharmacological tools or (pre-) candidates with established therapeutic orientations for clinical proof of concept, either within sanofi-aventis or with external partners. JEAN-MARC HERBERT Executive Vice président Early-to-Candidate Entrepreneurial Unit

9 -9- Key Areas Regenerative Medicine / Stem Cells Emerging Platforms Technologies Deliver clinical candidates (advantage of novel small molecule library in Tucson) to enrich the company s R&D portfolio in key therapeutic areas by partnering: Aging Internally Externally

10 -10- Progress opportunities that would otherwise languish in the valley of death

11 ONCOLOGY FIBROSIS & WOUND REPAIR INFECTIOUS DISEASES DIABETES -11- IMMUNO- INFLAMMATION AGING Our strategic vision within E2C focuses on six major areas with critical unmet medical needs AGING 11

12 Final Thoughts Cliquez pour modifier le style du titre -12- How can we interact? Each Entrepreneurial Unit has assigned interfaces Global network [Partnering Platform] Developing a partnering mindset Understand each others strategies, needs, etc

13 -13-13

14 -14- Contact Information for US: Paul R. Eynott, PhD US Head, Partnering & Innovation Early-to-Candidate Entrepreneurial Unit sanofi-aventis, US 2090 East Innovation Park Drive Oro Valley, Tucson Arizona, Office: (+1) Cell: (+1) Fax: (+1)